Work

The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials

Year: 2013

Type: review

Study designs: Systematic Review, Meta-Analysis

Source: Blood

DOI: 10.1182/blood.v122.21.356.356

Authors: Robert K. Hills, Stephen Petersdorf, Elihu H. Estey, Megan Othus, Frederick R. Appelbaum, Sylvie Castaigne, Herve Dombret, Sylvie Chevret, Jacques Delaunay, Norbert Ifrah, Jean-Yves Cahn, Christian Recher, Alan K Burnett

Institutions: Cardiff University, Seattle Cancer Care Alliance, University of Washington, Fred Hutch Cancer Center, Centre Hospitalier de Versailles, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Université Paris Diderot, Centre Hospitalier Universitaire de Nantes, Nantes Université, Centre Hospitalier Universitaire d'Angers, Centre Hospitalier Universitaire de Grenoble, Hôpital Purpan

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2295901697

FWCI: 0.659

Cites:

Cited by: 14

Related to: 10